cytoy
Lv3
270 积分
2022-07-20 加入
-
Real-world treatment patterns and outcomes for patients with advanced hepatocellular carcinoma initially treated with PD-1 inhibitors
17天前
已完结
-
Overexpression and gene amplification of EGFR, HER2, and HER3 in biliary tract carcinomas, and the possibility for therapy with the HER2-targeting antibody pertuzumab
1个月前
已完结
-
HER2 gene (ERBB2) amplification is a low-frequency driver with potential predictive value in gallbladder carcinoma
1个月前
已完结
-
Experimental HER2- targeted therapies for biliary tract cancer
1个月前
已完结
-
Successful immunotherapy with PD-1 Iinhibitor for advanced pancreatic cancer: report of two cases and review of literature
1个月前
已完结
-
Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial
3个月前
已完结
-
Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study
3个月前
已完结
-
Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study
3个月前
已完结
-
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study
8个月前
已完结
-
Landscape of cancer cell therapies: trends and real-world data
1年前
已完结